Journal of Medicinal Chemistry · 2009 · 107 citations · 58 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryEnzymologyStructure-activity RelationshipsBioactive Small MoleculesEnzyme InhibitionMarine Bioactive CompoundsMarine Drug DiscoveryMarine Natural ProductsPeptide Drug DiscoveryBioactive Marine PeptidesEnzyme Inhibitors From Marine SourcesMarine Cyanobacterial MetabolitesMarine-derived Enzyme InhibitorsMolecular Docking AnalysisMolecular Structure DeterminationProtease SelectivityStructural Basis Of Specificity
In our efforts to explore marine cyanobacteria as a source of novel bioactive compounds, we discovered a statine unit-containing linear decadepsipeptide, grassystatin A (1), which we screened against a diverse set of 59 proteases. We describe the structure determination of 1 and two natural analogues, grassystatins B (2) and C (3), using NMR, MS, and chiral HPLC techniques. Compound 1 selectively inhibited cathepsins D and E with IC(50)s of 26.5 nM and 886 pM, respectively. Compound 2 showed similar potency and selectivity against cathepsins D and E (IC(50)s of 7.27 nM and 354 pM, respectively), whereas the truncated peptide analogue grassystatin C (3), which consists of two fewer residues than 1 and 2, was less potent against both but still selective for cathepsin E. The selectivity of compounds 1-3 for cathepsin E over D (20-38-fold) suggests that these natural products may be useful tools to probe cathepsin E function. We investigated the structural basis of this selectivity using molecular docking. We also show that 1 can reduce antigen presentation by dendritic cells, a process thought to rely on cathepsin E.
58
The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling
Konstantin Arnold, Lorenza Bordoli, Jürgen Kopp et al. · Bioinformatics · 2005 · 7.1K citations · Full text
Jean‐Philippe Richard, Kamran Melikov, Éric Vivès et al. · Journal of Biological Chemistry · 2002 · 1.4K citations · Full text